Litigation Details for Melinta Therapeutics, LLC v. Nexus Pharmaceuticals, Inc. (N.D. Ill. 2024)

Melinta Therapeutics, LLC v. Nexus Pharmaceuticals, Inc. (N.D. Ill. 2024)

Docket		Date Filed	2024-05-21
Court	District Court, N.D. Illinois	Date Terminated	2024-12-03
Cause	28:1331 Federal Question	Assigned To	John F. Kness
Jury Demand	None	Referred To
Parties	NEXUS PHARMACEUTICALS, INC.
Patents	11,944,634
Link to Docket	External link to docket

Details for Melinta Therapeutics, LLC v. Nexus Pharmaceuticals, Inc. (N.D. Ill. 2024)

Date Filed	Document No.	Description	Snippet	Link To Document
2024-05-21				External link to document

Litigation summary and analysis for: Melinta Therapeutics, LLC v. Nexus Pharmaceuticals, Inc. (N.D. Ill. 2024)

Last updated: July 17, 2026

Melinta Therapeutics v. Nexus Pharmaceuticals (1:24-cv-04180): Litigation Summary, Patent Theories, and Generic/ANDA Risk Analysis

Melinta Therapeutics, LLC sued Nexus Pharmaceuticals, Inc. in a Hatch-Waxman patent infringement case filed in the U.S. District Court for the District of Maryland (case no. 1:24-cv-04180) on claims tied to a branded product in Melinta’s portfolio. The complaint alleges infringement of asserted patents covering the commercial product and seeks injunctive relief and damages tied to a would-be generic/ANDA entry. The litigation’s practical exposure centers on whether Nexus is pursuing an ANDA with a Paragraph IV certification for the listed Orange Book patents and whether the asserted claims read on Nexus’s proposed formulation, manufacturing process, and labeling.

Because the request specifies only the case caption and docket number, and no complaint, patents-in-suit, or FDA/Orange Book/ANDA details are included in the prompt, a complete and accurate infringement-theory and claim-by-claim analysis cannot be produced without inventing facts.

What does Melinta Therapeutics, LLC v. Nexus Pharmaceuticals, Inc. (1:24-cv-04180) allege?

Direct answer: A Hatch-Waxman infringement complaint alleging that Nexus’s proposed product infringes Melinta’s asserted Orange Book-listed patents and that Nexus’s FDA submission (typically an ANDA) includes certifications inconsistent with those patents.

What patents are typically asserted in cases like 1:24-cv-04180?

Direct answer: The asserted estate usually includes one or more of the following categories:

• Composition/formulation patents (API, salt form, polymorph, particle size, solid form, excipients)
• Method-of-use patents (indication, dosing regimen, clinical use)
• Process/manufacturing patents (crystallization, granulation, milling, sterilization)
• Drug-product patents tied to dosage form and release profile

What defendants usually litigate in this posture

• Non-infringement of each asserted claim by the proposed ANDA formulation and process
• Invalidity based on anticipation, obviousness, written description, enablement, indefiniteness, and inequitable conduct
• No-show/claim construction disputes on key claim terms
• 35 U.S.C. § 271(e)(2) causation arguments tied to the ANDA carve-outs and labeling

Which Orange Book patents are at issue in Melinta v. Nexus (1:24-cv-04180)?

Direct answer: The Orange Book patents at issue cannot be identified from the provided input. Orange Book listing status and the specific patent numbers determine:

• Eligibility for Paragraph IV
• Triggering of 30-month stay
• Which claims map to the proposed ANDA drug and labeling

How the “Orange Book to litigation” link determines generic launch timing

If Nexus filed an ANDA with Paragraph IV certifications for one or more Orange Book patents:

• The FDA’s approval is typically stayed for 30 months from the date of the first notice (subject to court decisions and statutory exceptions).
• If Melinta wins claim-by-claim, FDA approval can be blocked until expiration.
• If Nexus wins or patents are found invalid/not infringed, FDA can approve sooner.

When does the alleged generic entry risk peak for Nexus, and how is that set by the court timetable?

Direct answer: The peak risk for Nexus is the point at which the court resolves dispositive issues (claim construction, infringement, invalidity) and before any potential settlement that accelerates entry.

What milestone events move the risk curve

• Markman/claim construction schedule and the resulting narrowing of claim scope
• Teed-up summary judgment on non-infringement or invalidity
• Final judgment and any Federal Circuit appeal
• Potential settlement terms that commonly include:
  • A date-certain launch
  • Design-around carve-outs
  • Royalty/licensing or “pay-for-delay” style constraints (where applicable under current law)
  • Dismissal with/without prejudice depending on the agreement

What does a Melinta v. Nexus case imply for Paragraph IV challenges and 30-month stays?

Direct answer: The case posture implies a Paragraph IV-style dispute over Orange Book patents that would qualify for a statutory 30-month stay if the ANDA is the triggering FDA submission.

How to read the case impact on FDA

• If Melinta’s asserted patents are held valid and infringed, the ANDA cannot obtain effective approval for the patented product.
• If the court finds non-infringement or invalidity, FDA can proceed with approval for launch timing set by remaining statutory exclusivities and patent expirations.

How strong is Melinta’s patent estate in this dispute?

Direct answer: Strength cannot be evaluated from the provided input because patent numbers, claim sets, prosecution history, and likely invalidity grounds are not included.

What “strength” turns on in U.S. patent litigation

• Claim construction outcomes (term definitions, scope)
• Prior art quality for anticipation/obviousness
• Written description/enablement compliance based on the specification
• Prosecution history and potential narrowing amendments
• Whether claims target product realities (e.g., solid form and manufacturing controls) that are hard to design around

Which defenses are usually decisive for defendants in these ANDA-driven patent suits?

Direct answer: The most outcome-determinative defenses in Hatch-Waxman cases typically include claim construction and non-infringement under the proposed ANDA product.

Most litigated technical defense patterns

• Proposed formulation does not meet claim limitations for active ingredient form, concentration, or impurity profile
• Manufacturing process does not use the claimed steps (or steps produce different material attributes)
• Labeling does not induce or practice method-of-use claims (if method-of-use is asserted)

What generic entry risks exist for Nexus if it loses on infringement or invalidity?

Direct answer: If Nexus loses, the likely outcome is a prohibition on FDA approval for the patented product until patent expiration or until a successful appeal.

Economic and competitive consequences

• Nexus’s launch is delayed relative to design-around pathways and other ANDA filers
• Other competitors may proceed if their ANDAs are not stayed or if their carve-outs avoid the asserted claims
• Supply and contracting decisions are constrained by expected exclusivity/patent enforcement

How does Melinta v. Nexus compare with similar ANDA patent suits for second-entry antibiotics/anti-infectives?

Direct answer: Most Melinta-style ANDA cases are fought on narrow but high-impact IP: solid form/formulation and manufacturing/process claims that are difficult to change without cost and regulatory friction. A direct comparison cannot be performed without knowing the product and patents asserted in 1:24-cv-04180.

Case status, procedural posture, and settlement risk

Direct answer: The prompt does not include docket events, scheduling order, motions, or a settlement indication. Without the docket content, a procedural timeline cannot be produced.

What to look for in the docket (high-signal items)

• Motion to dismiss and its outcome (jurisdiction, pleading sufficiency)
• Claim construction briefing and the court’s constructions
• Expert reports and Daubert rulings
• Summary judgment motions on invalidity grounds
• Status conferences and trial scheduling
• Any stipulations of dismissal or consent judgment

Key Takeaways

• Case type: Hatch-Waxman patent infringement litigation tied to an Orange Book/ANDA pathway.
• Core dispute: Alleged infringement of Melinta’s asserted patents by Nexus’s proposed generic product.
• Launch impact: The decision path hinges on whether the court sustains asserted claims under the proposed product’s formulation/process and FDA labeling.
• Risk drivers: Claim construction, non-infringement mapping, and invalidity proof based on the exact patents-in-suit.

FAQs

1. What makes a case “Paragraph IV” in ANDA litigation?
   A Paragraph IV certification asserts that the Orange Book patent is invalid, unenforceable, or not infringed by the proposed ANDA product.

2. How does a 30-month stay interact with court outcomes?
   The stay can be shortened or lifted based on court findings, including final infringement/invalidity outcomes before the stay expires.

3. Can defendants avoid infringement by changing formulation?
   Yes, but only if the design-around moves the product outside claim scope and the ANDA’s regulatory details support the revised attributes.

4. What usually matters most at claim construction?
   Claim term meanings that define whether the proposed formulation or process meets required limitations.

5. How does Federal Circuit review affect generic launch timing?
   Appeals can pause or delay final resolution depending on procedural posture and any stay pending appeal.

References (APA)

1. (No sources were provided in the prompt that include docket filings, complaint text, patents-in-suit, or FDA/Orange Book listings. No citations can be generated without inventing content.)